logo Orixha

About us

Why Orixha ?

Scientific innovations and improved emergency care protocols have led to significant advances in pre-hospital care for cardiac arrest. Over the last decades, this translates into increasing initial resuscitation rates. However, in-hospital care remains the weak link in the chain of survival for out of hospital cardiac arrest. Current technological and pharmacological solutions, to tackle Post Cardiac Arrest Syndrome, are few and show weak efficacy. Hence, two-thirds of these resuscitated cardiac arrest patients trespass within hours from secondary death.

Orixha was created with this main objective in mind: improve the survival rate for cardiac arrest with utra-rapid hypothermia powered by liquid ventilation.

In 2018, Orixha was set-up by a team of researchers from Université de Sherbrooke, Qc, CA, Ecole Nationale Vétérinaire d’Alfort and INSEMR, Fr. This multinational team with clinical, pathophysiology and engineering expertise had worked together on the project in the academic setting for over 10 years. Developing several liquid ventilation prototypes, they had, by then, achieved a strong preclinical proof of concept for Lung Conservative Liquid Ventilation, with publications in leading scientific journals.

The name “Orixha” is a symbol of this fruitful teamwork between Canadian and French researchers as well as their dedication to a faster and more efficient hypothermia solution as it means “cold breath” and is associated with the northern wind for the Huron people.

The team

Photo Fabrice Paublant

Fabrice Paublant

CEO, co-founder

Fabrice Paublant holds a B.A. from ESSEC Business School in Paris and a M.B.A. from MIT Sloan School of Management, Cambridge, USA. Mr Paublant has been Export Director at Ipsen group for Eastern Europe. He has been consultant at Boston Consulting Group at Boston. During his 3 years at BCG, he mostly worked with pharmaceutical and biotech companies on strategic and operationnal aspects. En 2004, he founded Narval Laboratories for developping medical innovatives solutions for respiratory and sleep disorders.

Photo Renaud Tissier

Renaud Tissier

DVM, PhD, co-founder

Renaud Tissier is professor of pharmacy and toxicology and deputy director at Ecole Nationale Vétérinaire d'Alfort (EnvA France). He obtained his PhD in 2003 at Université Paris Sud. He has been coordinator of several research grants and published more than 100 scientific articles in peer-reviewed international reviews. He gave more than 100 conferences in national and international congresses.
Today, he is leading a research group working on the effect of hypothermia in post-cardiac arrest syndrome.

Photo Philippe Micheau

Philippe Micheau

Eng., PhD, co-founder

For the last 20 yers, Philippe Micheau has been conducted research work on engeeniring of medical devices in his laboratory at the University of Sherbrooke (Canada). The main goal of his laboratory is to develop technological solutions for liquid breathing.

Photo Mathieu Nadeau

Mathieu Nadeau

Eng., PhD, co-founder

Mathieu Nadeau is graduated in mechanical engeeniering from the University of Sherbrooke. Since 2010, he is developping new technological solutions for liquid ventilators. During his PhD, he developed a model for cooling during liquid ventilation.
He is now product development manager at Arjo's in Canada.

Photo Matthias Kohlhauer

Matthias Kohlhauer

DVM, PhD, co-founder

Matthias Kohlhauer worked during his PhD on the different applications of liquid ventilation at the Ecole Nationale Vétérinaire d'Alfort. During is post-doctoral fellowship, at University of Cambridge (UK), he worked on the physiopathology of myocardial infarction. He is now assistant professor in clinical pharmacology at Ecole Nationale Vétérinaire d'Alfort.

Our partners

Logo d'Erganeo Logo d'Activation Logo de Creative Eurecom Logo d'Infiplast Logo de WILCO Logo d'Agoranov Logo de BPI Logo de Eit Health